Cellyan Biotechnology Co., Ltd (HKPD) stock forecast & analysis
0.1569
NasdaqCM · USD
Down: -0.0246, -13.6%
1 analysis
- Open
- 0.1588
- Previous close
- 0.1815
- Day range
- 0.1566 – 0.1588
- 52-week range
- 0.1510 – 1.82
- Volume (shares)
- 6.06M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 41.35M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- Not available
- Market cap
- 7.61M
Market Scanner’s AI analysis of Cellyan Biotechnology Co., Ltd (HKPD), updated September 2026: HKPD's recent analyses highlighted significant revenue decline and bearish technical indicators.
Summary
HKPD's recent analyses highlighted significant revenue decline and bearish technical indicators.
Recent analyses for HKPD, a Medical Distribution company, covered a substantial year-over-year quarterly revenue decrease of 31.7%. The company reported negative TTM EPS, Profit Margin, ROE, and Operating Margin. Technical indicators presented a bearish outlook, with the price trading significantly below its 50-day and 200-day SMAs, and the RSI and MFI indicating extreme selling pressure.
HKPD technical picture
HKPD's technical indicators showed a strong downtrend, with the price closing significantly below its 50-day and 200-day SMAs. Momentum indicators like RSI and MFI suggested extreme selling pressure, while the MACD also indicated bearish momentum.
Fundamentals
HKPD reported a significant year-over-year quarterly revenue decline and negative trailing twelve months EPS, profit margin, ROE, and operating margin. The company's short-term liquidity appears healthy, and total debt decreased from the prior reporting period.
Factors discussed — upside
- Current Ratio of 3.859 and Quick Ratio of 1.694 indicate good short-term liquidity.
- Total Debt decreased from $2,272,684 to $1,258,164 between September 2025 and March 2026.
Factors discussed — risks
- Year-over-year quarterly revenue decline of 31.7%.
- Negative TTM EPS of -0.07.
- Negative TTM Profit Margin of -8.46%.
- Negative TTM ROE of -15.59%.
- Price trading significantly below 50-day and 200-day SMAs.
- Financial Performance
- Technical Indicators
- Liquidity
- Debt Levels
Summary updated .
HKPD technical indicators
Common technical indicators for HKPD, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.39 | Price below |
| 10-day exponential moving average | 0.31 | Price below |
| Relative strength index (14-day) | 22.79 | Oversold |
| MACD line (12/26/9) | -0.0417 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 0.23 – 0.52 | Price below the lower band |
Analyses
Recent HKPD.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Cellyan Biotechnology Co., Ltd?
- The company's short-term liquidity appears strong, supported by a Current Ratio of 3.859 and a Quick Ratio of 1.694. Additionally, total debt saw a significant reduction from $2,272,684 in September 2025 to $1,258,164 by March 2026.
- What are the risks for Cellyan Biotechnology Co., Ltd?
- The company faces headwinds from a substantial year-over-year quarterly revenue decline of 31.7%. Financial performance metrics are negative, including a trailing twelve months (TTM) Earnings Per Share (EPS) of -0.07, a Profit Margin of -8.46%, and a Return on Equity (ROE) of -15.59%. Technical indicators also suggest a bearish trend, with the stock price trading significantly below its 50-day and 200-day simple moving averages, and the Relative Strength Index (RSI) and Money Flow Index (MFI) indicating extreme selling pressure.
- Is Cellyan Biotechnology Co., Ltd bullish or bearish?
- Recent AI analyses of Cellyan Biotechnology Co., Ltd examined factors on both sides. Discussed upside: The company's short-term liquidity appears strong, supported by a Current Ratio of 3.859 and a Quick Ratio of 1.694. Additionally, total debt saw a significant reduction from $2,272,684 in September 2025 to $1,258,164 by March 2026. Discussed risks: The company faces headwinds from a substantial year-over-year quarterly revenue decline of 31.7%. Financial performance metrics are negative, including a trailing twelve months (TTM) Earnings Per Share (EPS) of -0.07, a Profit Margin of -8.46%, and a Return on Equity (ROE) of -15.59%. Technical indicators also suggest a bearish trend, with the stock price trading significantly below its 50-day and 200-day simple moving averages, and the Relative Strength Index (RSI) and Money Flow Index (MFI) indicating extreme selling pressure. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Cellyan Biotechnology Co., Ltd?
- Recent analyses for HKPD, a Medical Distribution company, covered a substantial year-over-year quarterly revenue decrease of 31.7%. The company reported negative TTM EPS, Profit Margin, ROE, and Operating Margin. Technical indicators presented a bearish outlook, with the price trading significantly below its 50-day and 200-day SMAs, and the RSI and MFI indicating extreme selling pressure.
- Bundles used
- gemini-low-v2
Run a fresh HKPD.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every HKPD.US report already in the library